Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
KRAS G12D was long seen as nearly untouchable. Ranok’s RNK08954 now has early clinical data, but the pivotal test is still ahead.
Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?
Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.
Draig Therapeutics DT-101 Phase 1 data put MEG biomarkers at the centre of depression trials
DT-101 may revive AMPA receptor depression research, but Phase 2 must prove safety signals can become real clinical benefit.
What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment
AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.
Avacta’s pre|CISION exatecan conjugate reaches Phase 1 as competition in targeted topo I inhibitors intensifies
Avacta opens Phase 1 trial of FAP-Exd (AVA6103) in four advanced solid tumors. Analysis of what the sustained-release exatecan conjugate must prove in 2026.
Scynexis expands SCY-247 program with IV SAD and MAD trial launch
SCYNEXIS advances IV SCY-247 into Phase 1 for invasive candidiasis. Explore what this means for resistance and regulation.
Why MIRA Pharmaceuticals is targeting chemotherapy-induced nerve pain with Ketamir-2
Find out how MIRA Pharmaceuticals aims to transform CIPN care with Ketamir-2 and why regulators and investors are watching its 2026 development milestones.
How Insilico Medicine’s ISM8969 could unlock a new class of neuroinflammatory drugs
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.
Enveda’s ENV-6946 enters Phase 1: Can a “multi-biologic in a pill” reshape the future of IBD therapy?
Can Enveda’s ENV-6946 deliver the efficacy of biologics in a pill for IBD? Find out why its triple-cytokine Phase 1 trial is drawing industry attention.
Janux Therapeutics advances masked EGFR T cell engager JANX008 into Phase 1 expansion
Janux Therapeutics pushes JANX008 into Phase 1 expansion across EGFR+ cancers. Discover how masking technology may shift the immunotherapy safety paradigm.